Hussman Strategic Advisors Inc. Increases Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY

Hussman Strategic Advisors Inc. increased its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 50.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 63,000 shares of the company’s stock after buying an additional 21,000 shares during the quarter. Hussman Strategic Advisors Inc.’s holdings in Harmony Biosciences were worth $2,357,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. National Bank of Canada FI bought a new stake in shares of Harmony Biosciences during the 3rd quarter worth approximately $40,000. Mirae Asset Global Investments Co. Ltd. raised its position in Harmony Biosciences by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,799 shares of the company’s stock valued at $105,000 after purchasing an additional 575 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Harmony Biosciences by 338.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,511 shares of the company’s stock valued at $111,000 after purchasing an additional 2,711 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in Harmony Biosciences during the 2nd quarter valued at $120,000. Finally, Prairiewood Capital LLC bought a new stake in Harmony Biosciences during the 4th quarter valued at $232,000. 86.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on HRMY shares. Truist Financial lowered Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Zacks Research lowered Harmony Biosciences from a “hold” rating to a “strong sell” rating in a research report on Thursday, March 26th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of Harmony Biosciences in a research report on Wednesday, February 25th. UBS Group decreased their target price on Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Finally, Bank of America reduced their price target on Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating for the company in a research report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $42.67.

Harmony Biosciences Trading Up 1.8%

HRMY opened at $31.83 on Friday. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of 11.75, a PEG ratio of 0.43 and a beta of 0.97. The company has a current ratio of 3.60, a quick ratio of 3.58 and a debt-to-equity ratio of 0.17. Harmony Biosciences Holdings, Inc. has a 12 month low of $25.52 and a 12 month high of $40.87. The stock has a fifty day moving average price of $28.76 and a 200-day moving average price of $32.87.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.38 EPS for the quarter, missing the consensus estimate of $0.84 by ($0.46). The company had revenue of $243.78 million during the quarter, compared to the consensus estimate of $240.04 million. Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The company’s revenue was up 21.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.85 earnings per share. As a group, equities research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.34 earnings per share for the current fiscal year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial?stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.